EGFR and non-small cell lung carcinoma: This suggests SOX9 acts downstream of Notch in KRAS-driven NSCLC, promoting invasion and metastasis, with potential indirect antagonism to EGFR signaling due to mutual exclusivity of KRAS/EGFR mutations (41).